These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9377570)

  • 1. Aclacinomycin A stabilizes topoisomerase I covalent complexes.
    Nitiss JL; Pourquier P; Pommier Y
    Cancer Res; 1997 Oct; 57(20):4564-9. PubMed ID: 9377570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
    Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
    Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
    Bridewell DJ; Finlay GJ; Baguley BC
    Oncol Res; 1997; 9(10):535-42. PubMed ID: 9507531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
    Zunino F; Capranico G
    Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
    Wasserman RA; Wang JC
    Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.
    Wasserman RA; Austin CA; Fisher LM; Wang JC
    Cancer Res; 1993 Aug; 53(15):3591-6. PubMed ID: 8393377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.
    Bjornsti MA; Benedetti P; Viglianti GA; Wang JC
    Cancer Res; 1989 Nov; 49(22):6318-23. PubMed ID: 2553253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
    Pawlik CA; Israel M; Sweatman TW; Lothstein L
    Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
    Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
    Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
    Wang LK; Rogers BD; Hecht SM
    Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
    Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
    Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
    Nitiss JL; Zhou J; Rose A; Hsiung Y; Gale KC; Osheroff N
    Biochemistry; 1998 Mar; 37(9):3078-85. PubMed ID: 9485461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential poisoning of topoisomerases by menogaril and nogalamycin dictated by the minor groove-binding nogalose sugar.
    Sim SP; Gatto B; Yu C; Liu AA; Li TK; Pilch DS; LaVoie EJ; Liu LF
    Biochemistry; 1997 Oct; 36(43):13285-91. PubMed ID: 9341219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
    Nitiss JL; Wang JC
    Mol Pharmacol; 1996 Nov; 50(5):1095-102. PubMed ID: 8913340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor.
    Hajji N; Mateos S; Pastor N; Domínguez I; Cortés F
    Mutat Res; 2005 May; 583(1):26-35. PubMed ID: 15866463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
    Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.